Galectin Therapeutics beats by $0.01
- Reports Q2 (Jun) loss of $0.14 per share, $0.01 better thanthe single analyst estimate of ($0.15).
- As of August 11, 2017, 130 patients (80%) have completed all 52 weeks of infusions in the Company's NASH-CX Phase 2b Clinical Trial. Approximately 99% of the entire study's total number of infusions have been administered.
- Company remains on track to report top line data from the NASH-CX Phase 2b Clinical Trial in December 2017.
- As of June 30, 2017, the Company had $9.1 million of non-restricted cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through December 31, 2017.
No comments:
Post a Comment